BR112023019479A2 - Forma cristalina de um inibidor de shp2 - Google Patents
Forma cristalina de um inibidor de shp2Info
- Publication number
- BR112023019479A2 BR112023019479A2 BR112023019479A BR112023019479A BR112023019479A2 BR 112023019479 A2 BR112023019479 A2 BR 112023019479A2 BR 112023019479 A BR112023019479 A BR 112023019479A BR 112023019479 A BR112023019479 A BR 112023019479A BR 112023019479 A2 BR112023019479 A2 BR 112023019479A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline form
- shp2 inhibitor
- relates
- compositions
- dihydrospiro
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- HZCJDRDHKWNUGN-GOSISDBHSA-N NC1=NC=CC(=C1Cl)SC1=CN=C(N=N1)N1CCC2(CC1)[C@@H](C1=CC=CC=C1C2)N Chemical compound NC1=NC=CC(=C1Cl)SC1=CN=C(N=N1)N1CCC2(CC1)[C@@H](C1=CC=CC=C1C2)N HZCJDRDHKWNUGN-GOSISDBHSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
forma cristalina de um inibidor de shp2, composição farmacêutica, combinação e usos. a presente invenção refere-se a uma forma cristalina de hemi-hidrato de base livre de (s)-1'-(6-((2-amino-3-cloropiridin-4-il)tio)-1,2,4-triazin-3-il)-1,3-di-hidroespiro[indeno-2,4'-piperidin]-1-amina (forma 1). a invenção também se refere a composições farmacêuticas compreendendo esta forma cristalina, e a métodos de utilização da forma cristalina e de tais composições para o tratamento de crescimento celular anormal, tal como câncer, em um mamífero.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169340P | 2021-04-01 | 2021-04-01 | |
| US202263321902P | 2022-03-21 | 2022-03-21 | |
| PCT/IB2022/052982 WO2022208408A1 (en) | 2021-04-01 | 2022-03-30 | Crystalline form of a shp2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019479A2 true BR112023019479A2 (pt) | 2023-12-05 |
Family
ID=81327112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019479A BR112023019479A2 (pt) | 2021-04-01 | 2022-03-30 | Forma cristalina de um inibidor de shp2 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4313307A1 (pt) |
| JP (1) | JP2024513798A (pt) |
| KR (1) | KR20230165309A (pt) |
| AU (1) | AU2022252094A1 (pt) |
| BR (1) | BR112023019479A2 (pt) |
| CA (1) | CA3215295A1 (pt) |
| WO (1) | WO2022208408A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| CN113711012A (zh) | 2018-09-14 | 2021-11-26 | 联合利华知识产权控股有限公司 | 免洗型化妆品组合物保护皮肤免受污染的功效的评估 |
| JP7284830B2 (ja) | 2019-04-02 | 2023-05-31 | アレイ バイオファーマ インコーポレイテッド | タンパク質チロシンホスファターゼ阻害剤 |
-
2022
- 2022-03-30 WO PCT/IB2022/052982 patent/WO2022208408A1/en active Application Filing
- 2022-03-30 CA CA3215295A patent/CA3215295A1/en active Pending
- 2022-03-30 AU AU2022252094A patent/AU2022252094A1/en active Pending
- 2022-03-30 KR KR1020237037693A patent/KR20230165309A/ko active Search and Examination
- 2022-03-30 BR BR112023019479A patent/BR112023019479A2/pt unknown
- 2022-03-30 EP EP22715194.1A patent/EP4313307A1/en active Pending
- 2022-03-30 JP JP2023559680A patent/JP2024513798A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022208408A1 (en) | 2022-10-06 |
| AU2022252094A1 (en) | 2023-10-12 |
| EP4313307A1 (en) | 2024-02-07 |
| CA3215295A1 (en) | 2022-10-06 |
| KR20230165309A (ko) | 2023-12-05 |
| JP2024513798A (ja) | 2024-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023019479A2 (pt) | Forma cristalina de um inibidor de shp2 | |
| HN2005000212A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| CO2022016377A2 (es) | Inhibidores de kras tricíclicos fusionados | |
| PE20071138A1 (es) | Derivados de pirimidina como inhibidores de quinasas | |
| ECSP066406A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| CY1117193T1 (el) | Φαρμακευτικη συνθεση για θεραπεια ή αποτροπη γλαυκωματος | |
| BR0317435A (pt) | Derivados de pirimidina para o tratamento do crescimento celular anormal | |
| ECSP066997A (es) | Derivados de pirimidina para tratar el crecimiento celular anómalo | |
| TN2012000265A1 (en) | Triazolopyridines | |
| BRPI0810411B8 (pt) | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica | |
| PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION | |
| UY27834A1 (es) | Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos. | |
| CO6630187A2 (es) | 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak | |
| BR112017028604A2 (pt) | forma cristalina de base livre de lorlatinibe | |
| BRPI0313942C1 (pt) | derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas | |
| UY32046A (es) | Derivados de 2-alquil-6-cicloamino-3-(piridin-4-il)imidazoz[1,2-b]-piridazina, su preparación y su aplicación en terapéutica | |
| MX2022006086A (es) | Derivados de piridopirimidinona como antagonistas de ahr. | |
| MX2021002051A (es) | Imidazo[1,2-b]piridaziinas como inhibidores de trk. | |
| PE20070167A1 (es) | COMPUESTOS 5H-BENZO[4,5]CICLOHEPTA[1,2-b]PIRIDINA COMO INHIBIDORES DE TIROSINA QUINASA | |
| ECSP045477A (es) | COMPUESTOS DE AMIDAS DE ÁCIDO3-AMINO-TIENO[2,3-b]PIRIDINO-2-CARBOXÍLICO SUSTITUIDOY PROCEDIMIENTOS PARA PREPARARLOS Y SUS USOS. | |
| BR112022002518A2 (pt) | Compostos de alquinila quinazolina | |
| CO2023010694A2 (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| BR0306915A (pt) | Composto, composição, uso de um composto, e, métodos para inibir a telomerase in vitro ou in vivo, para regular a proliferação celular in vitro ou in vivo, e para tratamento de uma condição proliferativa | |
| CL2023002635A1 (es) | Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1 | |
| UY32280A (es) | DERIVADOS DE 6-CICLOAMINO-3-(1H-PIRROLO[2,3-b]PIRIDIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA |